Resisting the resistance. Is there progress in maintaining antimicrobial efficacy?

D.H. Lloyd, Eva Varjonen

Research output: Chapter in Book/Report/Conference proceedingConference contribution


The major health threat caused by multiple drug resistance affecting both human and animal welfare, and the anticipation there will be limited future availability of new antibiotics, particularly in veterinary medicine. Moxifloxacin, similar to pradofloxacin in veterinary medicine, is one of the key antimicrobials used in Streptococcus pneumoniae infections in human medicine. The drug has been on the market since 2000 in North America, and no changes to S. pneumoniae susceptibility to this antimicrobial have been seen. This indicates that the antimicrobial is adequately dosed for this particular organism and has the right mechanisms for treating this particular organism to reduce selective pressure and resistance development. Work in recent years has aimed to assess the influence of the number of infectious organisms on antimicrobial susceptibility and resistance. This chapter discusses the risks associated with use and/or abuse of antimicrobial treatment. It also talks about the use of probiotics and faecal microbiota transplantation (FMT).
Original languageEnglish
Title of host publicationAdvances in Veterinary Dermatology
EditorsSheila Torres, Roudebush Philip
Number of pages205
ISBN (Electronic)9781119278368
ISBN (Print)9781119278351
Publication statusPublished - 14 Jun 2017


Dive into the research topics of 'Resisting the resistance. Is there progress in maintaining antimicrobial efficacy?'. Together they form a unique fingerprint.

Cite this